Celonic: Soenke Brunswieck appointed as Vice President Cell & Gene Therapy

Swiss biologics CDMO Celonic has appointed Soenke Brunswieck as VP cell & gene therapy to establish the organization’s new portfolio of CDMO services in the cell and gene therapy domain. "Cell & gene therapy represents a new paradigm in human health, with the potential to resolve unmet medical needs to improve patients’ lives through effective and safe advanced therapeutic medicinal products (ATMPs)", said Dr. Konstantin Matentzoglu, CEO at Celonic. "Celonic appointed Soenke specifically for his extensive expertise with platform technologies and manufacturing of cell & gene therapy products". Soenke has a track record as director of business development and project management at PharmaCell (now Lonza Netherlands). Prior to PharmaCell, he was the director of marketing & sales at CellGenix for over 10 years and was responsible for the creation and successful growth of the global market for GMP-reagents used in cell and gene therapy.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.